On July 28, 2022 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, reported it will present data from two ongoing clinical trials for recurrent glioblastoma and leptomeningeal metastases at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), being held August 12-13, 2022 in Toronto, Canada (Press release, Cytori Therapeutics, JUL 28, 2022, View Source [SID1234617071]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of oral presentation:
Title LOCL-04: Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases [LM] Phase 1/2a dose
Date August 12, 2022 from 2:15 – 4:00 p.m. ET
Session Oral abstract, Session 3: Enhancing Local and Compartmental Therapies
Presenter Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-LM clinical trial
Details of poster presentation:
Title LOCL-08: Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT Phase 1 Trial
Date August 12, 2022 from 6:20 – 8:20 p.m. ET
Session Poster display, Poster and Networking Reception
Presenter Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-GBM clinical trial
Electronic posters will be made available online at the start of the conference in addition to the in-person poster reception on Friday evening, August 12, 2022. For more information visit View Source
A copy of the posters will also be available under the Presentations tab of the Investors section of the Company’s website at the time of the presentations at View Source